Clinical Trials Browser

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

76 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07518654 2026-04-08

ThINKK-01

Phase 1 Not yet recruiting

12 enrolled

CNSLymphoidOther hematologic neoplasm

Paroxysmal nonkinesigenic dyskinesia, Leukemia, Neoplasm Metastasis, Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

ThINKK-01

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

B7-H3.CD28Z.CART in Solid Tumors

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

AKA-NBL

NEUROBLASTOTEP

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China

Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Determining Patterns In Study Experiences of Neuroblastoma Patients

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma